PET radiotracer market seen reaching $3.95 billion by 2030

The global PET radiotracer market was valued at $2.54 billion in 2025 and is projected to reach $3.95 billion by 2030, according to The Business Research Company. Growth is tied to cancer diagnoses, precision imaging demand, theranostics and wider use in neurology and cardiology.

Why it matters: - PET radiotracers are central to medical imaging for cancer, neurological disorders and cardiovascular conditions. - The market’s projected climb signals rising demand for more precise diagnostic tools across healthcare systems. - Expanding use in infectious disease detection adds another clinical use case.

What happened: - The Business Research Company released a market study on the global PET radiotracer market. - The market reached $2.54 billion in 2025. - The market is forecast to rise to $2.78 billion in 2026. - The market is projected to reach $3.95 billion by 2030. - The forecast implies a 9.2% compound annual growth rate through 2030. - The report was released from London on August 25, 2026. - More information is available in the full report. - A free sample is available through the sample report.

The details: - The report links past growth to increasing cancer diagnoses, more nuclear medicine centers, broader adoption of FDG-based imaging, cyclotron infrastructure and growth in diagnostic imaging services. - Future growth is tied to demand for precision diagnostics, more funding for radiopharmaceutical R&D, broader theranostics use and higher PET imaging adoption in neurology and cardiology. - The report says approvals for new radiotracers are making the regulatory environment more favorable. - PET radiotracers are radioactive substances injected before PET scans to detect biological targets inside the body. - The scans help clinicians visualize metabolic processes and spot abnormalities. - The market study says infectious diseases are a major demand driver. - PET radiotracers can help detect infections by highlighting metabolic activity and inflammation. - That can support diagnosis, treatment monitoring and differentiation between infectious and non-infectious conditions. - A February 2024 UK Health Security Agency report cited a 10.7% rise in tuberculosis cases in England in 2023, to 4,850 from 4,380 the year before.

Between the lines: - The report points to a market moving from niche oncology use toward broader clinical utility across multiple specialties. - The 9.2% CAGR suggests radiotracer demand is being supported by both technology adoption and expanding disease burden. - North America led the market in 2025, reflecting advanced healthcare infrastructure and high adoption rates. - Asia-Pacific is expected to be the fastest-growing regional market over the forecast period. - The regional analysis also covers South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - The 2026 report series adds market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based dashboards, market hotspots infographics, and updated technology and future-trend analysis.

What's next: - The market is expected to keep expanding through 2030 as precision diagnostics and theranostics gain broader use. - New radiotracer approvals could further support growth if regulatory momentum continues. - Asia-Pacific may narrow the gap with North America as regional demand accelerates. - The company provided media contact details for further inquiries, including Saumya Sahay and Oliver Guirdham, plus phone numbers, email and social links. - The company's announcement and social pages are available through its LinkedIn profile, Facebook page and X account.